Shield Therapeutics and Viatris sign collaborative sales agreement for Accrufer in the United States.
Shield Therapeutics plc, a commercial stage pharmaceutical company focused on the commercialization of Accrufer/Feraccru (ferric maltol), announced that it has entered into an exclusive, multi-year agreement with Viatris Inc. to co-commercialize Accrufer (ferric maltol), a novel, oral iron therapy differentiated from other conventional irons by its efficacy, well-tolerated formulation, and broad indication, in the United States